How much did Genedrive achieve in EBIT for the current year?
In the current year, Genedrive has achieved an EBIT of 494,580.5 GBP.
Genedrive EBIT 2025
Genedrive EBIT
494,580.5 GBP
Ticker
GDR.L
ISIN
GB00B1VKB244
WKN
A0ML2T
In 2025, Genedrive's EBIT was 494,580.5 GBP, a -35.8% increase from the 770,387.3 GBP EBIT recorded in the previous year.
The Genedrive EBIT history
| YEAR | EBIT (undefined GBP) |
|---|---|
| 2025e | 494.58 |
| 2024e | 770.39 |
| 2023 | -5,224 |
| 2022 | -5,615 |
| 2021 | -5,482 |
| 2020 | -5,640 |
| 2019 | -4,449 |
| 2018 | -5,264 |
| 2017 | -5,004 |
| 2016 | -5,426 |
| 2015 | -4,040 |
| 2014 | -2,300 |
| 2013 | -1,520 |
| 2012 | -840 |
| 2011 | 390 |
| 2010 | 310 |
| 2009 | -700 |
| 2008 | -1,450 |
| 2007 | -1,240 |
| 2006 | -800 |
| 2005 | 50 |
| 2004 | -250 |
Genedrive Revenue, EBIT, Net Income GB00B1VKB244 · A0ML2T
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Genedrive, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Genedrive from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Genedrive’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Genedrive. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Genedrive’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Genedrive’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Genedrive’s growth potential.
Genedrive Revenue, EBIT and net profit per share
| Date | Genedrive Revenue | Genedrive EBIT | Genedrive Net Income |
|---|---|---|---|
| 2025e | 60.25 M undefined | 494,580.5 undefined | 71.29 M undefined |
| 2024e | 29.45 M undefined | 770,387.3 undefined | 28.51 M undefined |
| 2023 | 55,000 undefined | -5.22 M undefined | -5.15 M undefined |
| 2022 | 49,000 undefined | -5.62 M undefined | -4.68 M undefined |
| 2021 | 687,000 undefined | -5.48 M undefined | -691,000 undefined |
| 2020 | 1.06 M undefined | -5.64 M undefined | -19.42 M undefined |
| 2019 | 2.36 M undefined | -4.45 M undefined | -3.64 M undefined |
| 2018 | 1.94 M undefined | -5.26 M undefined | -5.97 M undefined |
| 2017 | 2.62 M undefined | -5 M undefined | -6.44 M undefined |
| 2016 | 5.06 M undefined | -5.43 M undefined | -5.92 M undefined |
| 2015 | 4.52 M undefined | -4.04 M undefined | -3.03 M undefined |
| 2014 | 5.76 M undefined | -2.3 M undefined | -1.69 M undefined |
| 2013 | 5.36 M undefined | -1.52 M undefined | -1.16 M undefined |
| 2012 | 5.56 M undefined | -840,000 undefined | -240,000 undefined |
| 2011 | 5.75 M undefined | 390,000 undefined | 390,000 undefined |
| 2010 | 5.74 M undefined | 310,000 undefined | 290,000 undefined |
| 2009 | 3.97 M undefined | -700,000 undefined | 80,000 undefined |
| 2008 | 2.07 M undefined | -1.45 M undefined | -1.15 M undefined |
| 2007 | 1.36 M undefined | -1.24 M undefined | -1.04 M undefined |
| 2006 | 900,000 undefined | -800,000 undefined | -630,000 undefined |
| 2005 | 1.25 M undefined | 50,000 undefined | 60,000 undefined |
| 2004 | 700,000 undefined | -250,000 undefined | -220,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 700,000 GBP | -250,000 GBP | -220,000 GBP |
| 2005 | 1.25 M GBP | 50,000 GBP | 60,000 GBP |
| 2006 | 900,000 GBP | -800,000 GBP | -630,000 GBP |
| 2007 | 1.36 M GBP | -1.24 M GBP | -1.04 M GBP |
| 2008 | 2.07 M GBP | -1.45 M GBP | -1.15 M GBP |
| 2009 | 3.97 M GBP | -700,000 GBP | 80,000 GBP |
| 2010 | 5.74 M GBP | 310,000 GBP | 290,000 GBP |
| 2011 | 5.75 M GBP | 390,000 GBP | 390,000 GBP |
| 2012 | 5.56 M GBP | -840,000 GBP | -240,000 GBP |
| 2013 | 5.36 M GBP | -1.52 M GBP | -1.16 M GBP |
| 2014 | 5.76 M GBP | -2.3 M GBP | -1.69 M GBP |
| 2015 | 4.52 M GBP | -4.04 M GBP | -3.03 M GBP |
| 2016 | 5.06 M GBP | -5.43 M GBP | -5.92 M GBP |
| 2017 | 2.62 M GBP | -5 M GBP | -6.44 M GBP |
| 2018 | 1.94 M GBP | -5.26 M GBP | -5.97 M GBP |
| 2019 | 2.36 M GBP | -4.45 M GBP | -3.64 M GBP |
| 2020 | 1.06 M GBP | -5.64 M GBP | -19.42 M GBP |
| 2021 | 687,000 GBP | -5.48 M GBP | -691,000 GBP |
| 2022 | 49,000 GBP | -5.62 M GBP | -4.68 M GBP |
| 2023 | 55,000 GBP | -5.22 M GBP | -5.15 M GBP |
| 2024e | 29.45 M GBP | 770,387.3 GBP | 28.51 M GBP |
| 2025e | 60.25 M GBP | 494,580.5 GBP | 71.29 M GBP |
Genedrive stock margins GB00B1VKB244 · A0ML2T
The Genedrive margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Genedrive. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Genedrive.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Genedrive's sales revenue. A higher gross margin percentage indicates that the Genedrive retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Genedrive's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Genedrive's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Genedrive's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Genedrive. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Genedrive's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Genedrive Margin History
| Genedrive Gross margin | Genedrive Profit margin | Genedrive EBIT margin | Genedrive Profit margin |
|---|---|---|---|
| 2025e | -7,036.36 % | 0.82 % | 118.32 % |
| 2024e | -7,036.36 % | 2.62 % | 96.81 % |
| 2023 | -7,036.36 % | -9,498.18 % | -9,363.64 % |
| 2022 | -7,795.92 % | -11,459.18 % | -9,540.82 % |
| 2021 | -556.04 % | -797.96 % | -100.58 % |
| 2020 | -7,036.36 % | -532.58 % | -1,833.71 % |
| 2019 | -7,036.36 % | -188.36 % | -153.94 % |
| 2018 | -7,036.36 % | -271.62 % | -307.89 % |
| 2017 | -7,036.36 % | -191.07 % | -245.74 % |
| 2016 | 35.12 % | -107.17 % | -116.83 % |
| 2015 | 12.93 % | -89.44 % | -66.97 % |
| 2014 | 22.05 % | -39.93 % | -29.34 % |
| 2013 | 29.1 % | -28.36 % | -21.64 % |
| 2012 | 26.08 % | -15.11 % | -4.32 % |
| 2011 | 46.61 % | 6.78 % | 6.78 % |
| 2010 | 52.96 % | 5.4 % | 5.05 % |
| 2009 | 38.79 % | -17.63 % | 2.02 % |
| 2008 | 27.05 % | -70.05 % | -55.56 % |
| 2007 | 18.38 % | -91.18 % | -76.47 % |
| 2006 | 22.22 % | -88.89 % | -70 % |
| 2005 | 52.8 % | 4 % | 4.8 % |
| 2004 | 37.14 % | -35.71 % | -31.43 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 37.14 % | -35.71 % | -31.43 % |
| 2005 | 52.8 % | 4 % | 4.8 % |
| 2006 | 22.22 % | -88.89 % | -70 % |
| 2007 | 18.38 % | -91.18 % | -76.47 % |
| 2008 | 27.05 % | -70.05 % | -55.56 % |
| 2009 | 38.79 % | -17.63 % | 2.02 % |
| 2010 | 52.96 % | 5.4 % | 5.05 % |
| 2011 | 46.61 % | 6.78 % | 6.78 % |
| 2012 | 26.08 % | -15.11 % | -4.32 % |
| 2013 | 29.1 % | -28.36 % | -21.64 % |
| 2014 | 22.05 % | -39.93 % | -29.34 % |
| 2015 | 12.93 % | -89.44 % | -66.97 % |
| 2016 | 35.12 % | -107.17 % | -116.83 % |
| 2017 | -7,036.36 % | -191.07 % | -245.74 % |
| 2018 | -7,036.36 % | -271.62 % | -307.89 % |
| 2019 | -7,036.36 % | -188.36 % | -153.94 % |
| 2020 | -7,036.36 % | -532.58 % | -1,833.71 % |
| 2021 | -556.04 % | -797.96 % | -100.58 % |
| 2022 | -7,795.92 % | -11,459.18 % | -9,540.82 % |
| 2023 | -7,036.36 % | -9,498.18 % | -9,363.64 % |
| 2024e | -7,036.36 % | 2.62 % | 96.81 % |
| 2025e | -7,036.36 % | 0.82 % | 118.32 % |
Genedrive Aktienanalyse
What does Genedrive do?
Genedrive PLC is a biomedical company based in Manchester, United Kingdom, specializing in the development of innovative diagnostic tests for infectious diseases and cancer. The company was founded in 2007 under the name Epistem Limited and went public in 2013. The business model of Genedrive involves developing and distributing innovative molecular diagnostic tests for diseases worldwide. The company's main goal is to change the way infectious diseases and cancer are diagnosed and treated by offering rapid, accurate, and cost-effective tests. The company has two main divisions: Genprobe and Instruments. Under Genprobe, various in vitro diagnostic tests for infectious diseases and diseases of the human immune system, including tuberculosis, hepatitis C, hepatitis B, HIV, and others, are offered. Under Instruments, Genedrive offers PCR instruments used for analyzing samples for DNA and RNA sequences. Some of Genedrive's key products include: - Genedrive HCV-ID Testkit: A test kit for identifying and quantifying hepatitis C viruses (HCV) in human blood samples. The test provides results within 90 minutes and has high accuracy. - Genedrive MT-RNR1 Testkit: A test kit for the rapid diagnosis of tuberculosis (TB), one of the most common infectious diseases worldwide. The test utilizes PCR technology and provides results within 90 minutes. - Genedrive Genedrive 96: An instrument for simultaneous analysis of up to 96 PCR samples. The system offers high accuracy and precision in analyzing RNA and DNA sequences. The company collaborates closely with leading research institutions and health organizations worldwide to improve its products and develop new tests. Genedrive has formed partnerships with the British government, the US Department of Defense, and other institutions. In recent years, the company has made significant progress in developing new diagnostic tests for infectious diseases and cancer. For example, Genedrive recently signed an agreement with the Foundation for Innovative New Diagnostics (FIND) to develop a molecular test for the Ebola virus. The company also has a pipeline of projects, including tests for COVID-19 and antibiotic resistance. Despite Genedrive's success, the company remains committed to innovation and research in order to transform the diagnostics industry and improve the health of people worldwide. Genedrive is expected to continue playing an important role in the fight against infectious diseases and cancer in the future. Genedrive ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Genedrive's EBIT
Genedrive's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Genedrive's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Genedrive's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Genedrive’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Genedrive stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Genedrive.
How has the EBIT of Genedrive developed in recent years?
The EBIT of Genedrive has increased by -35.801% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Genedrive?
The EBIT of Genedrive is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Genedrive pay?
Over the past 12 months, Genedrive paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Genedrive is expected to pay a dividend of 0 GBP.
What is the dividend yield of Genedrive?
The current dividend yield of Genedrive is .
When does Genedrive pay dividends?
Genedrive pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Genedrive?
Genedrive paid dividends every year for the past 0 years.
What is the dividend of Genedrive?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is Genedrive located?
Genedrive is assigned to the 'Health' sector.
Wann musste ich die Aktien von Genedrive kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Genedrive from 1/28/2025 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 1/28/2025.
When did Genedrive pay the last dividend?
The last dividend was paid out on 1/28/2025.
What was the dividend of Genedrive in the year 2024?
In the year 2024, Genedrive distributed 0 GBP as dividends.
In which currency does Genedrive pay out the dividend?
The dividends of Genedrive are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Genedrive
Our stock analysis for Genedrive Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genedrive Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
